The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.
Integrase-defective lentiviral vectors: progress and applications
Abstract
Lentiviral vectors (LVs) offer the advantages of a large packaging capacity, broad cell tropism or specific cell-type targeting through pseudotyping, and long-term expression from integrated gene cassettes. However, transgene integration carries a risk of disrupting gene expression through insertional mutagenesis and may not be required for all applications. A non-integrating LV may be beneficial in cases in which transient gene expression is desired. Several recent publications outline the development and initial biological characterization of such vectors. Here, we discuss the potential applications and new directions for the development of integration-defective LVs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, class I mutations are limited in affecting the integrase multimerisation, linear episome processing, and DNA binding [25], as listed in Table 3.”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [25]
In the citing paper
“Class II mutations can be performed by exchanging the standard gag or pol packaging plasmid with an IN mutant strain [25].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [25]
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein‐Bey‐Abina, S., Deist, F. L., Carlier, F., Bouneaud, C., Hue, C., de Villartay, J., Thrasher, A. J., Wulffraat, N. M., Sorensen, R., Dupuis‐Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,102
Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R., Beitzel, B. F., Schröder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 1,002
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845
Research works printed but not linked: 2
- Goff SP . Retroviridae: the retroviruses and their replication. In: David M Knipe PMH, Diane E Griffin, Malcolm A Martin, Robert A Lamb, Bernard Roizman, Stephen E Strauss (ed). Fields Virology, 4th edn, vol. 2. Lippincott Williams & Wilkins: Philadelphia, 2001. pp 1871–1940.
- Lombardo A, Cesana D, Genovese P, Provasi E, Maruggi G, Binini C et al. Characterization of potential genomic ‘safe harbor’ for efficient targeted gene addition with zinc finger nucleases. Mol Ther 2009; 17: S168.
Cited by
Sorted by citations
Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
Kaufmann, K. B., Büning, H., Galy, A. H. M., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 300
Engineering mesenchymal stem cells for regenerative medicine and drug delivery
Park, J. S., Suryaprakash, S., Lao, Y., & Leong, K. W. (2015) · Methods · doi:10.1016/j.ymeth.2015.03.002 · Cited by 252
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F. D., & Stasi, A. D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 206
The role of unintegrated DNA in HIV infection
Sloan, R. D., & Wainberg, M. A. (2011) · Retrovirology · doi:10.1186/1742-4690-8-52 · Cited by 155
Metadata
- Authors
- Banasik, M. B., & McCray, P. B.
- Affiliations
- University of Iowa (US)
- Corresponding author
- McCray, P B
- ORCID
- McCray, P B
- Venue
- Gene Therapy
- Published
- 2009-10-22
- Volume
- 17
- Issue
- 2
- Pages
- 150-157
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W1964810194
- Cited by
- 129
- References
- 87
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 10 · 2015: 10 · 2014: 16 · 2013: 8 · 2012: 17
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- lentiviral vectors, non-integrating vectors, insertional mutagenesis, transient expression, pseudotyping, cell tropism, gene therapy vectors
- MeSH terms
- Animals, Genetic Vectors, Genetic Therapy, Gene Expression, Lentivirus, Mutagenesis, Insertional, Virus Integration, Gene Transfer Techniques, Transgenes, Integrases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
